Eagle Asset Management’s ADMA Biologics ADMA Stock Holding History

Eagle Asset Management’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-25,957	Closed	-$117K	–	561
2023 Q4	$117K	Buy	25,957 +4,367	+20%	+$16.2K	﹤0.01%	548
2023 Q3	$77.3K	Hold	21,590	–	–	﹤0.01%	530
2023 Q2	$79.7K	Buy	21,590 +2,217	+11%	+$8.22K	﹤0.01%	526
2023 Q1	$64K	Buy	19,373 +6,544	+51%	+$22.6K	﹤0.01%	537
2022 Q4	$49K	Buy	+12,829	New	+$39.6K	﹤0.01%	528
2022 Q3	–	Sell	-28,833	Closed	-$57K	–	545
2022 Q2	$57K	Hold	28,833	–	–	﹤0.01%	552
2022 Q1	$52K	Buy	28,833 +10,281	+55%	+$16K	﹤0.01%	572
2021 Q4	$24K	Hold	18,552	–	–	﹤0.01%	596
2021 Q3	$20K	Hold	18,552	–	–	﹤0.01%	590
2021 Q2	$29K	Hold	18,552	–	–	﹤0.01%	597
2021 Q1	$33K	Buy	18,552 +2,310	+14%	+$5.29K	﹤0.01%	591
2020 Q4	$31K	Buy	16,242 +5,790	+55%	+$12.2K	﹤0.01%	551
2020 Q3	$22K	Buy	+10,452	New	+$28.7K	﹤0.01%	567

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Eagle Asset Management's ADMA Position: Q1 2024 in Review

Eagle Asset Management sold out of ADMA Biologics (ADMA) in Q1 2024, closing a stake of 25,957 shares — an estimated $117K sold.

Eagle Asset Management first reported a position in ADMA in Q3 2020 and held it in 13 quarters. The position peaked at $117K in Q4 2023. 214 funds tracked by Wall St. Rank hold ADMA as of Q1 2024.

Eagle Asset Management reported no remaining ADMA Biologics position as of Q1 2024 after selling out during the quarter.
Eagle Asset Management sold 25,957 ADMA Biologics shares in Q1 2024, an estimated $117K.
Eagle Asset Management first reported a position in ADMA Biologics in Q3 2020 and held it in 13 quarters.
Eagle Asset Management's ADMA Biologics position peaked at $117K in Q4 2023.
214 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2024.

Based on Eagle Asset Management's 13F filing for Q1 2024, filed 9 May 2024.